Ada Health Financial Model

• Conversational, AI-driven symptom assessment app ("Ada") using diagnostic reasoning to triage users and navigate them to appropriate care.
• Three core pillars: (1) diagnostic information via conversational interface; (2) access - direct connection to healthcare professionals; (3) management - symptom/condition tracking and personal health profile.
• Available in 10 languages; tests thousands of diseases and symptoms to a "gold standard".
• 9+ years of R&D; 230 employees, ~50 medical experts.
• Positioning: highest diagnostic accuracy, advice safety on par with GPs, and highest consumer satisfaction among symptom-assessment apps.

Not explicitly stated in deck. The following can be inferred from the partner list and product positioning:

• B2B enterprise licensing: health systems, insurers, and pharma partners (Sutter Health, SANTÉCLAIR, Pfizer, Takeda, Labor Berlin, Samsung, Botnar, Obékan) likely pay API/white-label access fees or per-assessment fees to embed Ada's clinical AI. Rationale: deck emphasises "adaptable and scalable, provider agnostic" and "trusted partner for clinical AI".
• Consumer app revenue: freemium model with potential premium subscription or upsell to teleconsultation. Rationale: app is free to download (cited as "most popular"); monetisation route not stated.
• No pricing, contract sizes, or revenue figures disclosed in deck.

• 10M+ users
• 20M+ assessments completed
• Available in 10 languages
• 230 employees, ~50 medical experts
• 4.7 / 5.0 average app rating
• 270,000+ in-app ratings
• 266,000 five-star reviews vs. Comp. 1: 26k, Comp. 2: 61k, Comp. 3: 11k, Comp. 4: 10k - approximately 8x nearest competitor
• Partners: Sutter Health, SANTÉCLAIR, Pfizer, Takeda, Labor Berlin, Samsung, Botnar, Obékan
• NHS pilot (500+ patients, 20 doctors): 97% found Ada easy to use; 86% would use again; 15% would not have attended clinic had they used Ada first
• Care navigation metric: ">20%" ER use reduction indicated on chart
• No revenue, ARR, GMV, or growth-rate figures disclosed.

• Competitors named implicitly (Babylon cited by name in expert quote; four unnamed competitors shown in 5-star review chart).
• Moat claims:
• Clinical accuracy: 71% diagnostic accuracy vs. 38% competitor average (Gilbert et al., 2020, BMJ Open).
• Condition coverage: 99% - highest among competitors.
• Advice safety: 97% - on par with GPs vs. 90% competitor average.
• 9+ years of proprietary R&D and 20M+ assessment data flywheel.
• ~50 in-house medical experts - structural clinical investment competitors lack.
• Network of enterprise partners creates integration depth and switching costs.

• Co-founder & CEO: Daniel Nathrath - 20+ years experience; prior: BCG, viagogo, LYCOS.
• Co-founder & Chief Science Officer: Dr. Martin Hirsch, PhD - 25+ years experience.
• Co-founder & Chief Medical Officer: Dr. Claire Novorol, MD, PhD - 15+ years experience; NHS background.
• CTO: Urban Liebel, PhD - 25+ years experience; KIT background.

• Archetype + why: B2B SaaS / enterprise health-tech revenue model with a consumer volume overlay. Ada's primary value accrues through enterprise licensing deals (health systems, pharma, insurers), which are SaaS-like in structure (annual contracts, API seat/usage fees). A secondary consumer engagement layer (free app + potential premium) drives user scale, which in turn strengthens the enterprise data and sales proposition. Model should be a dual-stream SaaS + consumer P&L feeding into a unified 3-statement forecast.

• Forecast horizon & granularity: 5-year annual (2021–2025), with Year 1 broken into quarterly columns for cash planning given no revenue figures are disclosed and ramp dynamics matter.

• Key drivers & assumptions:

*Enterprise (B2B) stream:*

• Number of enterprise partners (contracts): 8 named as of May 2021; grow at 6–10 new logos/year - rationale: early-stage pipeline, large addressable partner universe.
• Average contract value (ACV): $200k–$500k/year per enterprise partner - rationale: health-system API integrations typically in this range; no deck data.
• Contract expansion / upsell rate: 15% NRR uplift - rationale: usage-based component (per-assessment) likely scales with patient volume.
• Enterprise gross margin: 70–75% - rationale: software delivery with clinical ops overhead; no deck data.

*Consumer (B2C) stream:*

• Monthly active users: derived from 10M+ total users; assume 15–20% MAU/install ratio = ~1.5–2M MAU.
• Consumer ARPU: $0–2/user/year - rationale: primarily free app; minimal monetisation disclosed; may be zero in near term.
• Consumer gross margin: 80%+ (pure software).

*Opex:*

• Headcount: 230 employees; average fully-loaded cost €120k/employee - rationale: Berlin HQ, mix of medical, tech, commercial.
• R&D as % of revenue: 35–45% in early years, declining toward 25% at scale.
• Sales & marketing: 20–30% of revenue - B2B enterprise sales motion, enterprise sales cycles are long.
• G&A: 10–15% of revenue.

*Clinical differentiation (model input, not driver):*

• Diagnostic accuracy: 71%; condition coverage: 99%; advice safety: 97% - used as qualitative moat support, not a financial driver per se.

• Scenarios (Base / Bull / Bear - which variables flex):
• Base: 8→18 enterprise logos over 5 years; ACV $250k; consumer ARPU $1; headcount grows 15%/year.
• Bull: Accelerated partnership wins (pharma real-world evidence use case drives faster closes), ACV expansion to $400k+, consumer premium tier launches.
• Bear: Enterprise sales cycles longer than modelled (12–18 months to close), ACV compression on smaller health-system deals, consumer remains entirely free.

• Required sheets / outputs:

1. Assumptions - all drivers in one place, tagged DECK vs. ASSUMED.
2. Enterprise Revenue - logo count × ACV × retention/expansion.
3. Consumer Revenue - MAU × ARPU.
4. P&L (Income Statement) - revenue, gross profit, operating expense lines, EBITDA.
5. Headcount Plan - by function (R&D, Medical, Commercial, G&A).
6. Cash Flow & Runway - given no funding ask is shown, model should show implied cash burn and months of runway at various raise sizes.
7. KPI Dashboard - MAU, enterprise logos, ACV, NRR, gross margin %, EBITDA margin %.